Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Regenxbio Inc (RGNX)

Regenxbio Inc (RGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
REGENXBIO Announces First Patient Dosed in Phase IIb/III NAAVIGATE Trial of Surabgene Lomparvovec in Diabetic Retinopathy; Company to Receive $100 Million Milestone PR Newswire - Mon Jun 29, 6:05AM CDT

ROCKVILLE, Md. , June 29, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the first patient has been dosed in the Phase IIb/III NAAVIGATE clinical trial of investigational surabgene...

RGNX : 15.33 (+0.66%)
REGENXBIO Completes Dosing in Confirmatory Study of RGX-202, Marking Completion of Registrational Development Program and Supporting Planned BLA Submission in Q3 2026 PR Newswire - Wed Jun 24, 6:05AM CDT

ROCKVILLE, Md. , June 24, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced the successful completion of dosing in the confirmatory study of RGX-202, a potential best-in-class gene...

RGNX : 15.33 (+0.66%)
REGENXBIO Announces Alignment with FDA on Path Forward for NAVSUNLI™ BLA Resubmission for Accelerated Approval; First Potential Gene Therapy for MPS II PR Newswire - Mon Jun 22, 6:30AM CDT

ROCKVILLE, Md. , June 22, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it has aligned with the U.S. Food and Drug Administration (FDA) regarding the next steps needed for...

RGNX : 15.33 (+0.66%)
REGENXBIO to Participate in Upcoming Investor Conferences PR Newswire - Mon May 18, 3:05PM CDT

ROCKVILLE, Md. , May 18, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:

RGNX : 15.33 (+0.66%)
RGNX: The Duchenne Data That Could Redefine Everything Investors Thought They Knew Barchart - Fri May 15, 4:02PM CDT

Barchart Research What to Expect from RGNX Earnings RGNX Generated May 15, 2026 Current Price $5.72 EPS Estimate $$0.21 Consensus Rating Strong Buy Average Move 4.28% RGNX: The Duchenne Data That Could...

RGNX : 15.33 (+0.66%)
Regenxbio: Q1 Earnings Snapshot AP - Thu May 14, 6:18AM CDT

Regenxbio: Q1 Earnings Snapshot

RGNX : 15.33 (+0.66%)
REGENXBIO Reports First Quarter 2026 Financial Results and Operational Highlights PR Newswire - Thu May 14, 6:10AM CDT

ROCKVILLE, Md. , May 14, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today reported financial results and operational highlights for the first quarter ended March 31, 2026.

RGNX : 15.33 (+0.66%)
REGENXBIO Announces Positive Topline Results from Pivotal Phase III AFFINITY DUCHENNE® Study of RGX-202 PR Newswire - Thu May 14, 6:00AM CDT

ROCKVILLE, Md. , May 14, 2026 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) announced positive topline and interim functional data from the pivotal Phase III portion of the Phase I/II/III AFFINITY...

RGNX : 15.33 (+0.66%)
REGENXBIO Duchenne Pivotal Data Lands Before Markets Adjust to Last Quarter's Miss Barchart - Sun May 10, 4:00PM CDT

Barchart Research What to Expect from RGNX Earnings RGNX Generated May 8, 2026 Current Price $10.55 EPS Estimate $$-1.36 Consensus Rating Strong Buy Average Move 4.28% REGENXBIO Duchenne Pivotal Data Lands...

RGNX : 15.33 (+0.66%)
REGENXBIO Duchenne Pivotal Data Lands Before Markets Adjust to Last Quarter's Miss Barchart - Sat May 9, 4:01PM CDT

Barchart Research What to Expect from RGNX Earnings RGNX Generated May 8, 2026 Current Price $10.55 EPS Estimate $$-1.36 Consensus Rating Strong Buy Average Move 4.28% REGENXBIO Duchenne Pivotal Data Lands...

RGNX : 15.33 (+0.66%)

Barchart Exclusives

Synopsys Stock Triggers a Massive Shift Away from Legacy Tech Barchart - 4 minutes ago
Synopsys is walking away from older manufacturing software as it pours money into AI chip design tools Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.